Immunovant Inc (IMVT) - Total Liabilities
Based on the latest financial reports, Immunovant Inc (IMVT) has total liabilities worth $66.26 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Immunovant Inc - Total Liabilities Trend (2018–2025)
This chart illustrates how Immunovant Inc's total liabilities have evolved over time, based on quarterly financial data. See Immunovant Inc current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Immunovant Inc Competitors by Total Liabilities
The table below lists competitors of Immunovant Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Reinet Investments S.C.A
AS:REINA
|
Netherlands | €2.00 Million |
|
First International Bank of Israel Ltd
TA:FIBI
|
Israel | ILA262.63 Billion |
|
L&K Engineering Co Ltd
TW:6139
|
Taiwan | NT$59.33 Billion |
|
Chengtun Mining Group Co Ltd
SHG:600711
|
China | CN¥30.91 Billion |
|
Amdocs Ltd
NASDAQ:DOX
|
USA | $2.88 Billion |
|
SHISEIDO CO. ADR
F:SHDA
|
Germany | €645.99 Billion |
|
Kodiak Gas Services, Inc.
NYSE:KGS
|
USA | $3.32 Billion |
Liability Composition Analysis (2018–2025)
This chart breaks down Immunovant Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see IMVT stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 15.74 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Immunovant Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Immunovant Inc (2018–2025)
The table below shows the annual total liabilities of Immunovant Inc from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | $68.78 Million | +40.49% |
| 2024-03-31 | $48.95 Million | +12.95% |
| 2023-03-31 | $43.34 Million | -5.24% |
| 2022-03-31 | $45.74 Million | +117.71% |
| 2021-03-31 | $21.01 Million | +37.15% |
| 2020-03-31 | $15.32 Million | +3926.31% |
| 2019-03-31 | $380.45K | -76.37% |
| 2018-03-31 | $1.61 Million | -- |
About Immunovant Inc
Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren's disease; and batoclimab for myasthenia gravis, chronic inflammatory demyelinating p… Read more